Revenue

Legal tech firm DISCO reports strong growth fueled by a 600% surge in AI revenue, launching agentic AI and a disruptive new all-in-one pricing model.

In its first report as a public company, Medline posts $28.4B in annual sales but faces declining net income from tariffs and IPO costs.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

While many cannabis firms struggle, Greenway Greenhouse reports a 40% revenue jump, expanding margins, and its fifth straight quarter of positive EBITDA.

As Kimco Realty prepares to present at the Raymond James conference, investors are watching for insights into its grocery-anchored retail strategy.

With its fifth straight EcoVadis Platinum rating and deep data transparency, ENNOVI is building a new blueprint for accountability in the industrial sector.

A new partnership is launching fully autonomous trucks on the busy Houston-Dallas route. What does this mean for logistics, safety, and Texas jobs?

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

A new Dubai-based VC firm is launching with a radical model: providing startups with a 24/7 AI workforce to slash costs and accelerate growth.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

The bank's Q1 earnings surge to $1.25B, driven by its Canadian Western Bank takeover and strategic deals, signaling aggressive pan-Canadian expansion.

Avista posts strong utility earnings but faces hurdles from investment losses and a key customer departure, unveiling a multi-billion dollar grid plan.

Rise Wellness launches its new 30g carbonated protein drink at Costco, betting on fizz and function to capture a rapidly growing, competitive market.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

Medtech giant reveals its 'Magnificent Seven' innovations and new data, with Chief Movement Officer Arnold Schwarzenegger leading the charge at AAOS 2026.

The fashion giant's revenue grew 11% in 2025, but net income fell sharply due to acquisition costs, tariffs, and a murky outlook for 2026.

With an $11.75M boost, a new device promises blood results in minutes, not hours, signaling a major pharma player's strategic pivot into diagnostics.